Person: SANCAR, MESUT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SANCAR
First Name
MESUT
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Metadata only Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study(ELSEVIER SCIENCE INC, 2020) ARMAN KANDIRMAZ, EMİNE; Oncel, Ibrahim; Sancar, Mesut; Konuskan, Bahadir; Arioz, Filiz; Tezcan, Songul; Arman-Kandirmaz, Emine; Parlak, Safak; Gumeler, Ekim; Anlar, BanuBackground: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis. Methods: A randomized, double-blind, placebo-controlled study was conducted in patients with subacute sclerosing panencephalitis assigned to receive two courses of aprepitant 250 mg/day orally or placebo for 15 days with an interval of two months between courses. Primary end points were safety and tolerability, and secondary end point was clinical improvement or stabilization assessed by subacute sclerosing panencephalitis scoring system. Electroencephalography (EEG), brain magnetic resonance imaging, and cerebrospinal fluid measles-specific immunoglobulin G index were evaluated before and after treatment. Results: Sixty-two patients with subacute sclerosing panencephalitis were allocated to aprepitant (n = 31, median age 18 years) or placebo (n = 31, median age 22 years) group. Fifteen patients left the study within the first six months and 12 patients left between six and 12 months. Aprepitant was well tolerated and treatment-associated adverse events were similar to those described in the treatment of nausea. Clinical status at six and 12 months' follow-up did not differ between aprepitant and placebo groups. Post-treatment EEG scores at 12 months were better in the aprepitant group (P = 0.015). Cerebral atrophy on magnetic resonance imaging increased in both groups, whereas measles-specific immunoglobulin G index decreased in the placebo group. Conclusions: In this first clinical trial of aprepitant treatment in patients with subacute sclerosing pan encephalitis, the drug was safe and well tolerated. No clinical effect was observed. A modest improvement in EEG findings might justify trials for longer periods because EEG changes can precede clinical findings in subacute sclerosing panencephalitis. (C) 2020 Elsevier Inc. All rights reserved.Publication Open Access The role of the clinical pharmacist in patient education and monitoring of patients under warfarin treatment(MARMARA UNIV, 2019-11-15) SANCAR, MESUT; Izzettin, Fikret Vehbi; Celik, Sevda; Acar, Rezzan Deniz; Tezcan, Songul; Aksoy, Nilay; Bektay, Muhammed Yunus; Sancar, MesutThis study was carried out on patients who were under anticoagulation treatment with warfarin, at the outpatient cardiology clinic. The aim was to determine the effectiveness of pharmacist consultation, education, and intervention on each patient's therapeutic results. A cross-sectional randomized trial has been done. Twenty-five patients were included in the study. The Oral Anticoagulation Knowledge (OAK) Test, Short Form-36 (SF-36) and Duke Anticoagulation Satisfaction Scale (DASS) were applied. Patients resumed their routine anticoagulation treatment and INR and complications were recorded during the study. Additionally, patients received patient education, consultation on lifestyle and anticoagulant usage issues from a pharmacist. The same tests were applied again to the patients on the 90th day of the study and the results were compared with the initial test. Maintenance of INR within the target range and complication rates were compared before and after the intervention. Pre-test and post-test results of the patients revealed statistically significant improvements on the physical and mental score components of the SF-36 (p = 0.001; p = 0.001), OAK test scores (p <= 0.001) and the (negative) limitations and burdens and positive effects components of the DASS (p = 0.005; p < 0.001; p = 0.001). The successful maintenance of INR within target range was significantly higher (p = 0.027). The positive effects of pharmacist consultation and education on therapeutic results were demonstrated.Publication Open Access Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer(BMJ PUBLISHING GROUP, 2018-03) SANCAR, MESUT; Tezcan, Songul; Izzettin, Fikret Vehbi; Sancar, Mesut; Turhal, Nazim Serdar; Yumuk, Perran FuldenObjective To determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer. Methods 36 Patients with colorectal cancer eligible for chemotherapy after surgery were included in the study. The patients were followed up during 3 courses of chemotherapy and individual pharmaceutical care plans were developed. The quality of life of patients was evaluated before and after the third course of chemotherapy. Results The incidence of drug-related problems (DRPs) in chemotherapy-treated patients was reduced in the 3rd course as compared with 1st course (63.9% vs 75%, respectively; n = 36; p > 0.05). The clinical oncology pharmacist gave 147 recommendations to patients, which were followed in 98% (n = 144) of cases. 91.7% (n = 132) of the recommendations of clinical oncology pharmacists solved the drug-related problems; however, the remaining 8.3% (n = 12) did not solve the problems and the patients were referred to a doctor for further investigations. The symptom-related quality of life of patients related to anaemia, diarrhoea and neurotoxicity was reduced after the third course of chemotherapy (p < 0.05). Conclusions The pharmaceutical care provided by the clinical oncology pharmacist has an important role in the identification and resolution of DRPs. Evaluation of symptom-related quality of life is important for the monitoring of patients receiving chemotherapy.Publication Metadata only Therapeutic drug monitoring of aprepitant with liquid chromatography–massspectrometry(2023-10-31) TEZCAN, SONGÜL; ARMAN KANDIRMAZ, EMİNE; SANCAR, MESUT; TEZCAN S., Kunal G., ÖZDEMİR F., ARMAN KANDIRMAZ E., SANCAR M.